Production (Stage)
MEI Pharma, Inc.
MEIP
$2.18
$0.03081.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -96.76% | -98.34% | -46.11% | 82.42% | -61.98% |
| Gross Profit | 96.76% | 98.34% | -103.01% | -515.99% | 33.38% |
| SG&A Expenses | -65.18% | -71.31% | -48.11% | -59.14% | -33.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -81.95% | -80.64% | -47.42% | -30.65% | -53.38% |
| Operating Income | 81.95% | 80.64% | -109.50% | 20.43% | 35.30% |
| Income Before Tax | 71.81% | 75.80% | -114.20% | -83.53% | 40.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 71.81% | 75.80% | -114.20% | -83.53% | 40.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.81% | 75.80% | -114.20% | -83.53% | 40.88% |
| EBIT | 81.95% | 80.64% | -109.50% | 20.43% | 35.30% |
| EBITDA | 81.79% | 80.50% | -108.82% | 20.91% | 35.45% |
| EPS Basic | 71.81% | 75.80% | -114.20% | -83.52% | 40.88% |
| Normalized Basic EPS | 82.77% | 86.28% | -108.70% | 17.46% | 35.90% |
| EPS Diluted | 71.81% | 75.80% | -114.20% | -83.52% | 40.88% |
| Normalized Diluted EPS | 82.77% | 86.28% | -108.70% | 17.46% | 35.90% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |